社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
Kita1a
🌈Never be enough !Never!never ,for me…
IP属地:吉林
+关注
帖子 · 74
帖子 · 74
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
Kita1a
Kita1a
·
06-13
$三倍做空半导体ETF-Direxion Daily(SOXS)$
看
1,905
回复
5
点赞
1
编组 21备份 2
分享
举报
Kita1a
Kita1a
·
06-10
靠
非常抱歉,此主贴已删除
看
84
回复
评论
点赞
1
编组 21备份 2
分享
举报
Kita1a
Kita1a
·
05-21
能不能不要跌了
远大医药(00512)核药伙伴Telix创新产品TLX101治疗初诊原发性胶质母细胞瘤海外I期研究迎关键进展 全球脑癌治疗再树新标杆
TLX101已获得美国FDA授予孤儿药资格认定,是全球范围内极具潜力的脑胶质瘤创新治疗方案。这标志着TLX101将成为首个进入胶质母细胞瘤III期开发的放射性药物疗法,临床开发进程持续领跑全球。未来若远大医药TLX101开发进展顺利,则有望提供全新的胶质母细胞瘤治疗手段,并为公司提供新的业绩增长点。
远大医药(00512)核药伙伴Telix创新产品TLX101治疗初诊原发性胶质母细胞瘤海外I期研究迎关键进展 全球脑癌治疗再树新标杆
看
352
回复
评论
点赞
1
编组 21备份 2
分享
举报
Kita1a
Kita1a
·
05-19
$TSLA 20260518 450.0 CALL$
[吃瓜]
看
624
回复
评论
点赞
2
编组 21备份 2
分享
举报
Kita1a
Kita1a
·
05-15
[汗颜]
地平线机器人-W回购1860万股股份,耗资约1.17亿港元
地平线机器人-W于2026年5月14日发布公告,披露在香港联交所场内回购1860万股B类普通股,约占本次回购前已发行股本的0.1271%。回购价格介乎每股6.20港元至6.33港元,总耗资约1.17亿港元。回购授权于2025年6月10日获通过,公司可根据该授权回购最多1,320,029,368股股份,目前已回购3,228.24万股,占授权通过当日已发行股本的0.2446%。公司表示,本次回购已获得董事会正式授权,并严格遵守香港联交所上市规则及相关法律法规的要求。
地平线机器人-W回购1860万股股份,耗资约1.17亿港元
看
387
回复
评论
点赞
1
编组 21备份 2
分享
举报
Kita1a
Kita1a
·
05-11
$远大医药(00512)$
割肉
看
732
回复
评论
点赞
1
编组 21备份 2
分享
举报
Kita1a
Kita1a
·
05-01
$INTC 20260508 100.0 CALL$
看
860
回复
评论
点赞
2
编组 21备份 2
分享
举报
Kita1a
Kita1a
·
04-23
$TSLA 20260529 350.0 PUT$
看
1,134
回复
评论
点赞
1
编组 21备份 2
分享
举报
Kita1a
Kita1a
·
04-23
🙄🙄🙄
董事会主席唐纬坤增持远大医药(00512)5万股 每股作价约6.47港元
香港联交所最新数据显示,4月22日,董事会主席唐纬坤增持远大医药(00512)5万股,每股作价6.472港元,总金额为32.36万港元。
董事会主席唐纬坤增持远大医药(00512)5万股 每股作价约6.47港元
看
708
回复
评论
点赞
1
编组 21备份 2
分享
举报
Kita1a
Kita1a
·
04-16
$泡泡玛特(09992)$
看
1,089
回复
评论
点赞
2
编组 21备份 2
分享
举报
加载更多
暂无关注
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"4192178964309222","uuid":"4192178964309222","gmtCreate":1729075808609,"gmtModify":1769175429383,"name":"Kita1a","pinyin":"kita1a","introduction":"","introductionEn":"","signature":"🌈Never be enough !Never!never ,for me…","avatar":"https://static.tigerbbs.com/fcbb5ec0f8aa53c53f347977db1fd9ae","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":21,"headSize":62,"tweetSize":74,"questionSize":0,"limitLevel":999,"accountStatus":1,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.03.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.09.25","exceedPercentage":"93.39%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.08.12","exceedPercentage":"80.47%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.05.08","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.10.23","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":5,"currentWearingBadge":{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.09.25","exceedPercentage":"93.87%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},"individualDisplayBadges":null,"crmLevel":6,"crmLevelSwitch":1,"location":"吉林","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":51,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":574537213784376,"gmtCreate":1781281750738,"gmtModify":1781281954674,"author":{"id":"4192178964309222","authorId":"4192178964309222","name":"Kita1a","avatar":"https://static.tigerbbs.com/fcbb5ec0f8aa53c53f347977db1fd9ae","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4192178964309222","authorIdStr":"4192178964309222"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/SOXS\">$三倍做空半导体ETF-Direxion Daily(SOXS)$ </a> ","listText":"<a href=\"https://laohu8.com/S/SOXS\">$三倍做空半导体ETF-Direxion Daily(SOXS)$ </a> ","text":"$三倍做空半导体ETF-Direxion Daily(SOXS)$","images":[{"img":"https://static.tigerbbs.com/b4542a80efaf0ece38bee3820d1219a4","width":"1074","height":"1644"},{"img":"https://static.tigerbbs.com/b75dbc6003da6d44b1f0321534c8ad0c","width":"1920","height":"2560"},{"img":"https://static.tigerbbs.com/380806da7506608d7822069f1581d06c","width":"1080","height":"1440"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/574537213784376","isVote":1,"tweetType":1,"viewCount":1905,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4179019632457472","authorId":"4179019632457472","name":"闯港美实现财富自由","avatar":"https://static.tigerbbs.com/281e6656868134ff238b8626ecc1f316","crmLevel":3,"crmLevelSwitch":1,"idStr":"4179019632457472","authorIdStr":"4179019632457472"},"content":"割了吧,15号又合股了","text":"割了吧,15号又合股了","html":"割了吧,15号又合股了"},{"author":{"id":"4176209230792292","authorId":"4176209230792292","name":"lx小白","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"idStr":"4176209230792292","authorIdStr":"4176209230792292"},"content":"又tm合股 才几个月啊 玩鸡毛 不玩了","text":"又tm合股 才几个月啊 玩鸡毛 不玩了","html":"又tm合股 才几个月啊 玩鸡毛 不玩了"}],"imageCount":3,"langContent":"EN","totalScore":0},{"id":573431716313696,"gmtCreate":1781027699969,"gmtModify":1781034157777,"author":{"id":"4192178964309222","authorId":"4192178964309222","name":"Kita1a","avatar":"https://static.tigerbbs.com/fcbb5ec0f8aa53c53f347977db1fd9ae","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4192178964309222","authorIdStr":"4192178964309222"},"themes":[],"title":"","htmlText":"靠","listText":"靠","text":"靠","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/573431716313696","repostId":"1159102593","repostType":2,"isVote":1,"tweetType":1,"viewCount":84,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":566649508189016,"gmtCreate":1779376479978,"gmtModify":1779376482501,"author":{"id":"4192178964309222","authorId":"4192178964309222","name":"Kita1a","avatar":"https://static.tigerbbs.com/fcbb5ec0f8aa53c53f347977db1fd9ae","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4192178964309222","authorIdStr":"4192178964309222"},"themes":[],"title":"","htmlText":"能不能不要跌了","listText":"能不能不要跌了","text":"能不能不要跌了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/566649508189016","repostId":"2637809470","repostType":2,"repost":{"id":"2637809470","kind":"news","pubTimestamp":1779339306,"share":"https://www.laohu8.com/m/news/2637809470?lang=zh_CN&edition=full","pubTime":"2026-05-21 12:55","market":"us","language":"zh","title":"远大医药(00512)核药伙伴Telix创新产品TLX101治疗初诊原发性胶质母细胞瘤海外I期研究迎关键进展 全球脑癌治疗再树新标杆","url":"https://stock-news.laohu8.com/highlight/detail?id=2637809470","media":"智通财经","summary":"TLX101已获得美国FDA授予孤儿药资格认定,是全球范围内极具潜力的脑胶质瘤创新治疗方案。这标志着TLX101将成为首个进入胶质母细胞瘤III期开发的放射性药物疗法,临床开发进程持续领跑全球。未来若远大医药TLX101开发进展顺利,则有望提供全新的胶质母细胞瘤治疗手段,并为公司提供新的业绩增长点。","content":"<html><body><p>智通财经APP获悉,近日,港股科技创新型国际化药企<a href=\"https://laohu8.com/S/00512\">远大医药</a>(00512)再度传来核药研发进展,公司全球创新放射性核素偶联药物(RDC) TLX101在海外开展的用于治疗初诊原发性胶质母细胞瘤(脑癌)的I期临床试验(IPAX-2)已完成全部患者入组,且未观察到剂量限制性毒性(DLT),包括使用最大给药剂量(两剂5GBq,总给药活性为10GBq)。</p><p>业内人士表示,TLX101有望打破胶质母细胞瘤传统治疗瓶颈,成为该领域开拓性的创新治疗手段,而此次海外临床里程碑突破,正是其临床价值与开发潜力的有力印证。随着远大医药创新核药产品全球化开发节奏持续加快,公司有望进一步夯实在核药这一全球蓝海市场的领先地位。</p><p><strong>TLX101临床获新突破,胶质母细胞瘤创新疗法全球领跑</strong></p><p>远大医药TLX101是一款用于治疗多形性胶质母细胞瘤的RDC药物,可自由通过血脑屏障进入大脑,并靶向胶质母细胞瘤过度表达的L型氨基酸转运蛋白1 (LAT-1)精准辐射癌细胞并促使其凋亡以达到治疗效果。这种“靶向+放疗”的双重作用模式,既能精准打击实体肿瘤,又能清除手术和放疗难以触及的微小转移灶,同时通过配套诊断试剂TLX101-CDx的PET成像技术,实现治疗前的精准患者分层。TLX101已获得美国FDA授予孤儿药资格认定,是全球范围内极具潜力的脑胶质瘤创新治疗方案。</p><p>本次开展的IPAX-2研究作为国际多中心、开放标签的I期剂量探索临床试验,旨在评估TLX101联合术后标准疗法(体外放射治疗和替莫唑胺)用于治疗初诊原发性胶质母细胞瘤的安全性与耐受性,研究覆盖澳大利亚、奥地利、荷兰四个研究中心,完成12例患者入组与三个剂量队列的递增探索。截至目前,研究已达到最大给药剂量,且全程未观察到剂量限制性毒性,安全性与耐受性数据表现优异,为后续关键临床试验的最大耐受剂量确定提供了坚实依据。患者在研究结束前将继续接受标准治疗,研究结束后将确认MTD作为主要终点。</p><p>与此同时,TLX101用于治疗复发性胶质母细胞瘤的关键性研究(IPAX BrIGHT)正在澳大利亚和荷兰积极入组患者并给药,同时也已在奥地利和比利时获批,即将开始患者入组。这标志着TLX101将成为首个进入胶质母细胞瘤III期开发的放射性药物疗法,临床开发进程持续领跑全球。</p><p>此前TLX101已完成的海外II期临床试验(IPAX-Linz研究)已初步验证TLX101的临床获益。临床结果表明,接受 TLX101治疗的复发性胶质母细胞瘤患者中位总生存期(OS)约为11.9个月(自初次诊断起约32.2个月),显著优于传统治疗方案,且整体安全性良好,未出现严重不良事件,为产品后续临床开发与应用奠定了扎实基础。</p><p>据悉,中枢神经系统肿瘤是全球第十大死亡原因,其中高达90%是脑肿瘤。胶质母细胞瘤来源于星形胶质细胞,占全部原发恶性中枢系统恶性肿瘤的50.1%,是最具侵袭性的原发性脑肿瘤之一,也被称为“癌症之王”。该疾病在世界卫生组织(WHO)分类中被列为4级,意味着恶性程度最高。我国脑胶质瘤年发病率约为6.4/10万人,其中胶质母细胞瘤年发病率为3~5/10万,诊断时的中位年龄为65岁。该肿瘤恶性程度高、复发率极高,即便接受手术、放疗、化疗联合标准治疗,患者中位生存期仅12-15个月,5年存活率约10%,长期以来存在巨大未被满足的临床需求。</p><p>根据贝哲斯咨询调研数据,2023年全球胶质母细胞瘤治疗市场容量已达75.22亿元人民币,预计到2029年全球胶质母细胞瘤治疗市场规模将会达到139.68亿元,年均复合增长率约8.8%。未来若远大医药TLX101开发进展顺利,则有望提供全新的胶质母细胞瘤治疗手段,并为公司提供新的业绩增长点。</p><p><strong>全链布局全球引领,远大医药核药抗肿瘤版图持续加固</strong></p><p>TLX101海外实现里程碑突破,不仅是产品临床开发的重要胜利,更是远大医药在核药抗肿瘤领域全球化布局、全产业链构建与诊疗一体化战略的深度兑现。近年来,远大医药持续深耕核药抗肿瘤赛道,以全球化视野搭建起覆盖研发、生产、配送、销售的全链条产业体系,成为全球核药抗肿瘤领域的领军企业。</p><p>在全球化布局层面,公司构建起以波士顿、成都为核心的研发基地,以波士顿、法兰克福、新加坡、成都为支撑的生产基地,搭配覆盖全球50多个国家和地区的商业化网络,实现创新核药从源头研发、规模化生产到全球推广的全流程贯通。同时,公司成都温江放射性药物研发及生产基地,作为全球首个核药全产业链闭环平台,实现同位素制备、核药研发、生产临床、商业化全链条自主可控,彻底破解核药领域“卡脖子”难题,为全球创新产品的快速产业化提供坚实保障,为公司实现了源头创新与全球临床开发能力。</p><p>在产品管线布局层面,公司坚定践行“诊疗一体化”核心理念,构建起多层次、高质量的核药创新<a href=\"https://laohu8.com/S/301365\">矩阵</a>。目前公司在研发注册阶段布局16款创新核药产品,涵盖68Ga、177Lu、131I、90Y、89Zr在内的5种关键放射性核素,全面覆盖肝癌、前列腺癌、肾癌、脑癌等七大高发癌种,形成诊断与治疗协同、多适应症覆盖的完善管线格局。截至目前,公司已有6款创新RDC药物进入注册临床研究,其中一款已进入NDA阶段,三款已进入III期临床阶段,是国内进入III期临床研究的诊断与治疗类RDC创新药储备最多的企业,在全球范围内也具备极为丰富的产品管线与诊疗一体化布局优势。</p><p><img src=\"https://img.zhitongcaijing.com/image/20260521/1779339500152581.png?x-oss-process=image/format,jpg/quality,q_90\" title=\"1779339500152581.png\"/></p><p>依托持续强化的全产业链壁垒与全球化创新能力,远大医药核药抗肿瘤板块保持高质量高速增长,核心产品放量与创新管线推进形成良性循环,创新壁垒产品收入占比持续提升,成为公司长期发展的核心增长引擎。本次TLX101海外临床突破,进一步深化了公司在脑癌领域的治疗布局,并验证了公司“Go Global”全球化发展战略。</p><p>远大医药表示,未来,公司将继续坚守以患者为中心的创新理念,持续加大全球核药领域的研发投入,加速重磅创新产品的临床推进与转化,不断丰富与完善核药产品管线与全产业链布局,以全球化运营、双循环发展的战略格局,持续巩固在全球核药抗肿瘤领域的领军地位,为攻克更多恶性肿瘤、提升全球患者生存质量、推动中国核药产业迈向世界前沿持续贡献力量。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>远大医药(00512)核药伙伴Telix创新产品TLX101治疗初诊原发性胶质母细胞瘤海外I期研究迎关键进展 全球脑癌治疗再树新标杆</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n远大医药(00512)核药伙伴Telix创新产品TLX101治疗初诊原发性胶质母细胞瘤海外I期研究迎关键进展 全球脑癌治疗再树新标杆\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-21 12:55 北京时间 <a href=http://www.zhitongcaijing.com/content/detail/1444370.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉,近日,港股科技创新型国际化药企远大医药(00512)再度传来核药研发进展,公司全球创新放射性核素偶联药物(RDC) TLX101在海外开展的用于治疗初诊原发性胶质母细胞瘤(脑癌)的I期临床试验(IPAX-2)已完成全部患者入组,且未观察到剂量限制性毒性(DLT),包括使用最大给药剂量(两剂5GBq,总给药活性为10GBq)。业内人士表示,TLX101有望打破胶质母细胞瘤传统治疗...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1444370.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK1191":"制药","00512":"远大医药"},"source_url":"http://www.zhitongcaijing.com/content/detail/1444370.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2637809470","content_text":"智通财经APP获悉,近日,港股科技创新型国际化药企远大医药(00512)再度传来核药研发进展,公司全球创新放射性核素偶联药物(RDC) TLX101在海外开展的用于治疗初诊原发性胶质母细胞瘤(脑癌)的I期临床试验(IPAX-2)已完成全部患者入组,且未观察到剂量限制性毒性(DLT),包括使用最大给药剂量(两剂5GBq,总给药活性为10GBq)。业内人士表示,TLX101有望打破胶质母细胞瘤传统治疗瓶颈,成为该领域开拓性的创新治疗手段,而此次海外临床里程碑突破,正是其临床价值与开发潜力的有力印证。随着远大医药创新核药产品全球化开发节奏持续加快,公司有望进一步夯实在核药这一全球蓝海市场的领先地位。TLX101临床获新突破,胶质母细胞瘤创新疗法全球领跑远大医药TLX101是一款用于治疗多形性胶质母细胞瘤的RDC药物,可自由通过血脑屏障进入大脑,并靶向胶质母细胞瘤过度表达的L型氨基酸转运蛋白1 (LAT-1)精准辐射癌细胞并促使其凋亡以达到治疗效果。这种“靶向+放疗”的双重作用模式,既能精准打击实体肿瘤,又能清除手术和放疗难以触及的微小转移灶,同时通过配套诊断试剂TLX101-CDx的PET成像技术,实现治疗前的精准患者分层。TLX101已获得美国FDA授予孤儿药资格认定,是全球范围内极具潜力的脑胶质瘤创新治疗方案。本次开展的IPAX-2研究作为国际多中心、开放标签的I期剂量探索临床试验,旨在评估TLX101联合术后标准疗法(体外放射治疗和替莫唑胺)用于治疗初诊原发性胶质母细胞瘤的安全性与耐受性,研究覆盖澳大利亚、奥地利、荷兰四个研究中心,完成12例患者入组与三个剂量队列的递增探索。截至目前,研究已达到最大给药剂量,且全程未观察到剂量限制性毒性,安全性与耐受性数据表现优异,为后续关键临床试验的最大耐受剂量确定提供了坚实依据。患者在研究结束前将继续接受标准治疗,研究结束后将确认MTD作为主要终点。与此同时,TLX101用于治疗复发性胶质母细胞瘤的关键性研究(IPAX BrIGHT)正在澳大利亚和荷兰积极入组患者并给药,同时也已在奥地利和比利时获批,即将开始患者入组。这标志着TLX101将成为首个进入胶质母细胞瘤III期开发的放射性药物疗法,临床开发进程持续领跑全球。此前TLX101已完成的海外II期临床试验(IPAX-Linz研究)已初步验证TLX101的临床获益。临床结果表明,接受 TLX101治疗的复发性胶质母细胞瘤患者中位总生存期(OS)约为11.9个月(自初次诊断起约32.2个月),显著优于传统治疗方案,且整体安全性良好,未出现严重不良事件,为产品后续临床开发与应用奠定了扎实基础。据悉,中枢神经系统肿瘤是全球第十大死亡原因,其中高达90%是脑肿瘤。胶质母细胞瘤来源于星形胶质细胞,占全部原发恶性中枢系统恶性肿瘤的50.1%,是最具侵袭性的原发性脑肿瘤之一,也被称为“癌症之王”。该疾病在世界卫生组织(WHO)分类中被列为4级,意味着恶性程度最高。我国脑胶质瘤年发病率约为6.4/10万人,其中胶质母细胞瘤年发病率为3~5/10万,诊断时的中位年龄为65岁。该肿瘤恶性程度高、复发率极高,即便接受手术、放疗、化疗联合标准治疗,患者中位生存期仅12-15个月,5年存活率约10%,长期以来存在巨大未被满足的临床需求。根据贝哲斯咨询调研数据,2023年全球胶质母细胞瘤治疗市场容量已达75.22亿元人民币,预计到2029年全球胶质母细胞瘤治疗市场规模将会达到139.68亿元,年均复合增长率约8.8%。未来若远大医药TLX101开发进展顺利,则有望提供全新的胶质母细胞瘤治疗手段,并为公司提供新的业绩增长点。全链布局全球引领,远大医药核药抗肿瘤版图持续加固TLX101海外实现里程碑突破,不仅是产品临床开发的重要胜利,更是远大医药在核药抗肿瘤领域全球化布局、全产业链构建与诊疗一体化战略的深度兑现。近年来,远大医药持续深耕核药抗肿瘤赛道,以全球化视野搭建起覆盖研发、生产、配送、销售的全链条产业体系,成为全球核药抗肿瘤领域的领军企业。在全球化布局层面,公司构建起以波士顿、成都为核心的研发基地,以波士顿、法兰克福、新加坡、成都为支撑的生产基地,搭配覆盖全球50多个国家和地区的商业化网络,实现创新核药从源头研发、规模化生产到全球推广的全流程贯通。同时,公司成都温江放射性药物研发及生产基地,作为全球首个核药全产业链闭环平台,实现同位素制备、核药研发、生产临床、商业化全链条自主可控,彻底破解核药领域“卡脖子”难题,为全球创新产品的快速产业化提供坚实保障,为公司实现了源头创新与全球临床开发能力。在产品管线布局层面,公司坚定践行“诊疗一体化”核心理念,构建起多层次、高质量的核药创新矩阵。目前公司在研发注册阶段布局16款创新核药产品,涵盖68Ga、177Lu、131I、90Y、89Zr在内的5种关键放射性核素,全面覆盖肝癌、前列腺癌、肾癌、脑癌等七大高发癌种,形成诊断与治疗协同、多适应症覆盖的完善管线格局。截至目前,公司已有6款创新RDC药物进入注册临床研究,其中一款已进入NDA阶段,三款已进入III期临床阶段,是国内进入III期临床研究的诊断与治疗类RDC创新药储备最多的企业,在全球范围内也具备极为丰富的产品管线与诊疗一体化布局优势。依托持续强化的全产业链壁垒与全球化创新能力,远大医药核药抗肿瘤板块保持高质量高速增长,核心产品放量与创新管线推进形成良性循环,创新壁垒产品收入占比持续提升,成为公司长期发展的核心增长引擎。本次TLX101海外临床突破,进一步深化了公司在脑癌领域的治疗布局,并验证了公司“Go Global”全球化发展战略。远大医药表示,未来,公司将继续坚守以患者为中心的创新理念,持续加大全球核药领域的研发投入,加速重磅创新产品的临床推进与转化,不断丰富与完善核药产品管线与全产业链布局,以全球化运营、双循环发展的战略格局,持续巩固在全球核药抗肿瘤领域的领军地位,为攻克更多恶性肿瘤、提升全球患者生存质量、推动中国核药产业迈向世界前沿持续贡献力量。","news_type":1,"symbols_score_info":{"00512":1.5}},"isVote":1,"tweetType":1,"viewCount":352,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":565630028654208,"gmtCreate":1779127649870,"gmtModify":1779127653957,"author":{"id":"4192178964309222","authorId":"4192178964309222","name":"Kita1a","avatar":"https://static.tigerbbs.com/fcbb5ec0f8aa53c53f347977db1fd9ae","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4192178964309222","authorIdStr":"4192178964309222"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/OPT/TSLA 20260518 450.0 CALL\">$TSLA 20260518 450.0 CALL$</a> [吃瓜] ","listText":"<a href=\"https://laohu8.com/OPT/TSLA 20260518 450.0 CALL\">$TSLA 20260518 450.0 CALL$</a> [吃瓜] ","text":"$TSLA 20260518 450.0 CALL$ [吃瓜]","images":[{"img":"https://static.tigerbbs.com/85f93aaa511927eb8cc4dad52d5e6a79","width":"1074","height":"1644"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/565630028654208","isVote":1,"tweetType":1,"viewCount":624,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"EN","totalScore":0},{"id":564196264503080,"gmtCreate":1778777619521,"gmtModify":1778777621484,"author":{"id":"4192178964309222","authorId":"4192178964309222","name":"Kita1a","avatar":"https://static.tigerbbs.com/fcbb5ec0f8aa53c53f347977db1fd9ae","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4192178964309222","authorIdStr":"4192178964309222"},"themes":[],"title":"","htmlText":"[汗颜] ","listText":"[汗颜] ","text":"[汗颜]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/564196264503080","repostId":"1157202885","repostType":2,"repost":{"id":"1157202885","kind":"news","weMediaInfo":{"introduction":"港美股公告全覆盖","home_visible":1,"media_name":"公告速递","id":"1097772564","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"pubTimestamp":1778766137,"share":"https://www.laohu8.com/m/news/1157202885?lang=zh_CN&edition=full","pubTime":"2026-05-14 21:42","market":"sh","language":"zh","title":"地平线机器人-W回购1860万股股份,耗资约1.17亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1157202885","media":"公告速递","summary":"地平线机器人-W于2026年5月14日发布公告,披露在香港联交所场内回购1860万股B类普通股,约占本次回购前已发行股本的0.1271%。回购价格介乎每股6.20港元至6.33港元,总耗资约1.17亿港元。回购授权于2025年6月10日获通过,公司可根据该授权回购最多1,320,029,368股股份,目前已回购3,228.24万股,占授权通过当日已发行股本的0.2446%。公司表示,本次回购已获得董事会正式授权,并严格遵守香港联交所上市规则及相关法律法规的要求。","content":"<p>地平线机器人-W(09660)于2026年5月14日发布公告,披露在香港联交所场内回购1860万股B类普通股,约占本次回购前已发行股本的0.1271%。回购价格介乎每股6.20港元至6.33港元,总耗资约1.17亿港元。</p>\n<p>公告显示,该公司回购完成后,其已发行股本(不包括库藏股)变动为12,495,213,315股,库藏股数量增至32,282,400股,合并后公司总股份数为12,527,495,715股。回购授权于2025年6月10日获通过,公司可根据该授权回购最多1,320,029,368股股份,目前已回购3,228.24万股,占授权通过当日已发行股本的0.2446%。</p>\n<p>公司表示,本次回购已获得董事会正式授权,并严格遵守香港联交所上市规则及相关法律法规的要求。上述信息由联席公司秘书赵奇签署。</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>地平线机器人-W回购1860万股股份,耗资约1.17亿港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n地平线机器人-W回购1860万股股份,耗资约1.17亿港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1097772564\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">公告速递 </p>\n<p class=\"h-time\">2026-05-14 21:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>地平线机器人-W(09660)于2026年5月14日发布公告,披露在香港联交所场内回购1860万股B类普通股,约占本次回购前已发行股本的0.1271%。回购价格介乎每股6.20港元至6.33港元,总耗资约1.17亿港元。</p>\n<p>公告显示,该公司回购完成后,其已发行股本(不包括库藏股)变动为12,495,213,315股,库藏股数量增至32,282,400股,合并后公司总股份数为12,527,495,715股。回购授权于2025年6月10日获通过,公司可根据该授权回购最多1,320,029,368股股份,目前已回购3,228.24万股,占授权通过当日已发行股本的0.2446%。</p>\n<p>公司表示,本次回购已获得董事会正式授权,并严格遵守香港联交所上市规则及相关法律法规的要求。上述信息由联席公司秘书赵奇签署。</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09660":"地平线机器人-W"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1157202885","content_text":"地平线机器人-W(09660)于2026年5月14日发布公告,披露在香港联交所场内回购1860万股B类普通股,约占本次回购前已发行股本的0.1271%。回购价格介乎每股6.20港元至6.33港元,总耗资约1.17亿港元。\n公告显示,该公司回购完成后,其已发行股本(不包括库藏股)变动为12,495,213,315股,库藏股数量增至32,282,400股,合并后公司总股份数为12,527,495,715股。回购授权于2025年6月10日获通过,公司可根据该授权回购最多1,320,029,368股股份,目前已回购3,228.24万股,占授权通过当日已发行股本的0.2446%。\n公司表示,本次回购已获得董事会正式授权,并严格遵守香港联交所上市规则及相关法律法规的要求。上述信息由联席公司秘书赵奇签署。","news_type":1,"symbols_score_info":{"09660":1}},"isVote":1,"tweetType":1,"viewCount":387,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":562936661958888,"gmtCreate":1778464251630,"gmtModify":1778464254637,"author":{"id":"4192178964309222","authorId":"4192178964309222","name":"Kita1a","avatar":"https://static.tigerbbs.com/fcbb5ec0f8aa53c53f347977db1fd9ae","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4192178964309222","authorIdStr":"4192178964309222"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/00512\">$远大医药(00512)$</a> 割肉","listText":"<a href=\"https://laohu8.com/S/00512\">$远大医药(00512)$</a> 割肉","text":"$远大医药(00512)$ 割肉","images":[{"img":"https://static.tigerbbs.com/1ba609481d464589de36bd7da6490d60","width":"1074","height":"1644"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/562936661958888","isVote":1,"tweetType":1,"viewCount":732,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":559565444306624,"gmtCreate":1777644419972,"gmtModify":1777644431658,"author":{"id":"4192178964309222","authorId":"4192178964309222","name":"Kita1a","avatar":"https://static.tigerbbs.com/fcbb5ec0f8aa53c53f347977db1fd9ae","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4192178964309222","authorIdStr":"4192178964309222"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/OPT/INTC 20260508 100.0 CALL\">$INTC 20260508 100.0 CALL$</a> ","listText":"<a href=\"https://laohu8.com/OPT/INTC 20260508 100.0 CALL\">$INTC 20260508 100.0 CALL$</a> ","text":"$INTC 20260508 100.0 CALL$","images":[{"img":"https://static.tigerbbs.com/26bd45a4bc341c16a038143b983964c3","width":"1074","height":"1644"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/559565444306624","isVote":1,"tweetType":1,"viewCount":860,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":556763526498048,"gmtCreate":1776957168434,"gmtModify":1776957180909,"author":{"id":"4192178964309222","authorId":"4192178964309222","name":"Kita1a","avatar":"https://static.tigerbbs.com/fcbb5ec0f8aa53c53f347977db1fd9ae","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4192178964309222","authorIdStr":"4192178964309222"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/OPT/TSLA 20260529 350.0 PUT\">$TSLA 20260529 350.0 PUT$ </a> ","listText":"<a href=\"https://laohu8.com/OPT/TSLA 20260529 350.0 PUT\">$TSLA 20260529 350.0 PUT$ </a> ","text":"$TSLA 20260529 350.0 PUT$","images":[{"img":"https://static.tigerbbs.com/dc8f2c5580e114bd6524906246ebf32d","width":"954","height":"1620"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/556763526498048","isVote":1,"tweetType":1,"viewCount":1134,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"EN","totalScore":0},{"id":556546808137400,"gmtCreate":1776904202878,"gmtModify":1776904205106,"author":{"id":"4192178964309222","authorId":"4192178964309222","name":"Kita1a","avatar":"https://static.tigerbbs.com/fcbb5ec0f8aa53c53f347977db1fd9ae","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4192178964309222","authorIdStr":"4192178964309222"},"themes":[],"title":"","htmlText":"🙄🙄🙄","listText":"🙄🙄🙄","text":"🙄🙄🙄","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/556546808137400","repostId":"2629046554","repostType":2,"repost":{"id":"2629046554","kind":"highlight","pubTimestamp":1776855412,"share":"https://www.laohu8.com/m/news/2629046554?lang=zh_CN&edition=full","pubTime":"2026-04-22 18:56","market":"sg","language":"zh","title":"董事会主席唐纬坤增持远大医药(00512)5万股 每股作价约6.47港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629046554","media":"智通财经网","summary":"香港联交所最新数据显示,4月22日,董事会主席唐纬坤增持远大医药(00512)5万股,每股作价6.472港元,总金额为32.36万港元。","content":"<html><body><div> <p>智通财经APP获悉,香港联交所最新数据显示,4月22日,董事会主席唐纬坤增持<a href=\"https://laohu8.com/S/00512\">远大医药</a>(00512)5万股,每股作价6.472港元,总金额为32.36万港元。增持后最新持股数目为111万股,最新持股比例为0.03%。</p> <div></div> </div></body></html>","source":"highlight_zhitongcaijin","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>董事会主席唐纬坤增持远大医药(00512)5万股 每股作价约6.47港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n董事会主席唐纬坤增持远大医药(00512)5万股 每股作价约6.47港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-22 18:56 北京时间 <a href=http://www.zhitongcaijing.com/content/detail/1432049.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉,香港联交所最新数据显示,4月22日,董事会主席唐纬坤增持远大医药(00512)5万股,每股作价6.472港元,总金额为32.36万港元。增持后最新持股数目为111万股,最新持股比例为0.03%。</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1432049.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://img.zhitongcaijing.com/image/20260422/20260422185722_69561.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","relate_stocks":{"00512":"远大医药","BK1191":"制药","EWH":"香港ETF-iShares MSCI"},"source_url":"http://www.zhitongcaijing.com/content/detail/1432049.html","is_english":false,"share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","article_id":"2629046554","content_text":"智通财经APP获悉,香港联交所最新数据显示,4月22日,董事会主席唐纬坤增持远大医药(00512)5万股,每股作价6.472港元,总金额为32.36万港元。增持后最新持股数目为111万股,最新持股比例为0.03%。","news_type":1,"symbols_score_info":{"00512":1.5,"EWH":1.5}},"isVote":1,"tweetType":1,"viewCount":708,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":554062457771752,"gmtCreate":1776303791708,"gmtModify":1776303804529,"author":{"id":"4192178964309222","authorId":"4192178964309222","name":"Kita1a","avatar":"https://static.tigerbbs.com/fcbb5ec0f8aa53c53f347977db1fd9ae","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4192178964309222","authorIdStr":"4192178964309222"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/09992\">$泡泡玛特(09992)$ </a><v-v data-views=\"1\"></v-v> ","listText":"<a href=\"https://laohu8.com/S/09992\">$泡泡玛特(09992)$ </a><v-v data-views=\"1\"></v-v> ","text":"$泡泡玛特(09992)$","images":[{"img":"https://static.tigerbbs.com/493bb517186689b79ec8fa8ba20a631c","width":"1074","height":"1644"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/554062457771752","isVote":1,"tweetType":1,"viewCount":1089,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"EN","totalScore":0}],"defaultTab":"following","isTTM":false}